1. At a Glance – The 90-Year-Old Pharma That Just Dropped an 81% Sales Bomb
₹236 crore market cap. ₹410 stock price. 22.6x P/E. 17.8% ROCE. Debt almost zero. And Q3 sales up 81% YoY.
Ladies and gentlemen, meet BDH Industries — incorporated in 1935. That’s right. This company is older than most independent countries and still showing up to work.
Latest Q3 FY26 numbers?
- Sales: ₹29.34 Cr
- PAT: ₹3.49 Cr
- EPS: ₹6.06
- Quarterly Sales Growth: 81.1% YoY
- Quarterly Profit Growth: 24.2% YoY
- 3-month return: 0.24%
- 1-year return: 42.5%
So the stock hasn’t moved much in 3 months, but earnings just delivered a caffeine shot.
It trades below industry P/E of 28.3.
It has a price-to-book of 3.34.
Dividend yield? 1.10%.
Interest coverage? 234. Yes, two hundred thirty four.
And debt? ₹0.03 Cr. That’s practically pocket change.
Now the real question:
Is this a hidden compounding machine… or just one good quarter flexing too hard?
Let’s investigate like a slightly suspicious but amused auditor.
2. Introduction – The Understated Veteran
BDH Industries is not your headline pharma giant.
No flashy TV ads.
No blockbuster molecule stories.
No dramatic USFDA drama.
Just a quiet, old-school Contract Manufacturing Organization doing therapeutic formulations across antifungal, antibiotics, oncology, anti-diabetic, psychotropic, cardiovascular… basically the entire pharmacy shelf.
And they export to:
USA, Canada, Latin America, Europe, CIS Russia, Gulf, Australia, Africa.
For a ₹236 crore company, that’s not bad global ambition.
FY23 revenue mix:
Revenue structure:
- 98% product sales
- 1% other operating income
- 1% other income
Which means: this business actually sells stuff. Not accounting tricks.
But here’s the twist.
Sales growth over 5 years? Just 2.26%.
3-year sales growth? -1.40%.
So suddenly this 81% quarterly sales growth looks… dramatic.
Is this sustainable momentum?
Or did someone finally wake up the sales team?
Let’s break it down.
3. Business Model – WTF Do They Even Do?
BDH Industries is essentially a Contract Manufacturing Organization (CMO).
Translation:
They manufacture pharma products for other companies.
Instead of building brands, they build pills.
Their manufacturing capacity (in millions):
- Tablets: 540
- Capsules: 180
- Ointments: 27
- Sterile Ointments: 14.4
